Header

UZH-Logo

Maintenance Infos

Huntington disease: natural history, biomarkers and prospects for therapeutics


Ross, Christopher A; Aylward, Elizabeth H; Wild, Edward J; Langbehn, Douglas R; Long, Jeffrey D; Warner, John H; Scahill, Rachael I; Leavitt, Blair R; Stout, Julie C; Paulsen, Jane S; Reilmann, Ralf; Unschuld, Paul G; Wexler, Alice; Margolis, Russell L; Tabrizi, Sarah J (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews. Neurology, 10(4):204-216.

Abstract

Huntington disease (HD) can be seen as a model neurodegenerative disorder, in that it is caused by a single genetic mutation and is amenable to predictive genetic testing, with estimation of years to predicted onset, enabling the entire range of disease natural history to be studied. Structural neuroimaging biomarkers show that progressive regional brain atrophy begins many years before the emergence of diagnosable signs and symptoms of HD, and continues steadily during the symptomatic or 'manifest' period. The continued development of functional, neurochemical and other biomarkers raises hopes that these biomarkers might be useful for future trials of disease-modifying therapeutics to delay the onset and slow the progression of HD. Such advances could herald a new era of personalized preventive therapeutics. We describe the natural history of HD, including the timing of emergence of motor, cognitive and emotional impairments, and the techniques that are used to assess these features. Building on this information, we review recent progress in the development of biomarkers for HD, and potential future roles of these biomarkers in clinical trials.

Abstract

Huntington disease (HD) can be seen as a model neurodegenerative disorder, in that it is caused by a single genetic mutation and is amenable to predictive genetic testing, with estimation of years to predicted onset, enabling the entire range of disease natural history to be studied. Structural neuroimaging biomarkers show that progressive regional brain atrophy begins many years before the emergence of diagnosable signs and symptoms of HD, and continues steadily during the symptomatic or 'manifest' period. The continued development of functional, neurochemical and other biomarkers raises hopes that these biomarkers might be useful for future trials of disease-modifying therapeutics to delay the onset and slow the progression of HD. Such advances could herald a new era of personalized preventive therapeutics. We describe the natural history of HD, including the timing of emergence of motor, cognitive and emotional impairments, and the techniques that are used to assess these features. Building on this information, we review recent progress in the development of biomarkers for HD, and potential future roles of these biomarkers in clinical trials.

Statistics

Citations

187 citations in Web of Science®
94 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 11 Feb 2015
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute for Regenerative Medicine (IREM)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:April 2014
Deposited On:11 Feb 2015 11:44
Last Modified:08 Dec 2017 10:30
Publisher:Nature Publishing Group
ISSN:1759-4758
Publisher DOI:https://doi.org/10.1038/nrneurol.2014.24
PubMed ID:24614516

Download